Cytokinetics Inc (CYTK): A Case For Going Higher

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Cytokinetics Inc is $7.22B. A total of 1.61 million shares were traded on the day, compared to an average of 3.64M shares.

In the most recent transaction, Malik Fady Ibraham sold 32,604 shares of CYTK for 67.56 per share on Mar 05 ’24. After the transaction, the EVP Research & Development now owns 138,973 company shares. In a previous transaction on Feb 14 ’24, HENDERSON JOHN T sold 5,000 shares at 76.48 per share. CYTK shares that Director owns now total 42,632.

Among the insiders who sold shares, Blum Robert I disposed of 12,500 shares on Feb 13 ’24 at a per-share price of $76.85. This resulted in the President & CEO holding 441,797 shares of CYTK after the transaction. In another insider transaction, Malik Fady Ibraham sold 32,605 shares at $79.30 per share on Feb 06 ’24. Company shares held by the EVP Research & Development now total 142,973.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CYTK has a high of $110.25 and a low of $25.98.

As of this writing, CYTK has an earnings estimate of -$1.14 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of -$0.89 per share and a lower estimate of -$1.36. The company reported an EPS of -$1.35 in the last quarter, which was -82.40% lower than expectations of -$0.74.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CYTK’s latest balance sheet shows that the firm has $471.64M in Cash & Short Term Investments as of fiscal 2021. There were $269.93M in debt and $71.86M in liabilities at the time. Its Book Value Per Share was -$3.80, while its Total Shareholder’s Equity was $243.86M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CYTK is Buy with a score of 4.56.

Most Popular

Related Posts